Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
|ClinicalTrials.gov Identifier: NCT01725360|
Recruitment Status : Completed
First Posted : November 12, 2012
Last Update Posted : August 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: montelukast||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Change of Airway Hyperresponsiveness to Mannitol and Methacholine During Intensified Anti-inflammatory Treatment in Patients With Asthma.|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||January 2012|
A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
Other Name: Singulair
- pd15 mannitol [ Time Frame: 4 weeks ]Improvement in pd15 mannitol over a treatment period of 4 weeks.
- pd20 methacholine [ Time Frame: 4 weeks ]change in pd20 methacholine over a treatment period of four weeks.
- Juniper asthma control questionnaire [ Time Frame: 4 weeks ]
- exhaled nitric oxide [ Time Frame: 4 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01725360
|University Hospital Bern|
|Bern, Switzerland, CH-3010|
|Principal Investigator:||Arthur Helbling, MD||University Hospital Bern Switzerland|